Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel (Axi-Cel) Therapy in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

被引：0

作者：

Lee, Dasom ^{[1
]}

Kambhampati, Swetha ^{[2
]}

Bobillo, Maria Silvina Odstrcil ^{[3
]}

Adedokun, Babatunde ^{[4
]}

Shadman, Mazyar ^{[5
,6
]}

Olson, Amanda L. ^{[7
]}

Herrera, Alex F. ^{[8
]}

Lee, Catherine J. ^{[5
,6
]}

Jacobson, Caron A. ^{[9
]}

Bye, Matthew ^{[10
]}

Hamadani, Mehdi ^{[10
]}

Kim, Soyoung ^{[11
]}

Dahiya, Saurabh ^{[12
]}

Hu, Zhen-Huan ^{[4
]}

Speth, Kelly ^{[4
]}

To, Christina ^{[4
]}

Mirjah, Debbie L. ^{[13
]}

Best, Timothy ^{[4
]}

Locke, Frederick L. ^{[14
]}

Ahmed, Nausheen ^{[15
]}

Tees, Michael T. ^{[16
]}

Pasquini, Marcelo C. ^{[17
]}

Ahmed, Sairah ^{[18
]}

机构：

[1] Stanford Univ, Div Hematol, Palo Alto, CA USA

[2] City Hope Natl Med Ctr, Yorba Linda, CA USA

[3] Univ Utah, Salt Lake City, UT USA

[4] Kite A Gilead Co, Santa Monica, CA USA

[5] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA USA

[6] Med Oncol Div, Seattle, WA USA

[7] Univ Texas MD Anderson Canc Ctr, Houston, TX USA

[8] City Hope Natl Med Ctr, Dept Hematol & Hematopoiet Cell Transplantat, Duarte, CA USA

[9] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA

[10] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Res CIBMTR, Milwaukee, WI USA

[11] Med Coll Wisconsin, Ctr Int Blood & Marrow Transplant Registry CIBMTR, CIBMTR Ctr Int Blood & Marrow Transplant Res, Milwaukee, WI USA

[12] Stanford Univ, Div Hematol, Stanford, CA USA

[13] Gilead Co, Santa Monica, CA USA

[14] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplant & Cellular Immunotherapy, Tampa, FL USA

[15] Univ Kansas, Div Hematol Malignancies & Cellular Therapeut, Med Ctr, Kansas City, KS USA

[16] Sarah Cannon transplant & Cellular Therapy Network, Nashville, TN USA

[17] Dana Farber Canc Inst, Boston, MA USA

[18] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma & Stem Cell Transplantat, Houston, TX USA

来源：

BLOOD | 2024年 / 144卷

关键词：

D O I：

10.1182/blood-2024-199139

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：527 / 528

页数：2

共 50 条

[21] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)
Abramson, Jeremy S.
Kamdar, Manali
Liu, Fei Fei
Crotta, Alessandro
Previtali, Alessandro
Klijn, Sven L.
Wang, Pearl
Situ, Aaron
Zhang, Yixie
Bonner, Ashley
Lunning, Matthew A.
BLOOD, 2022, 140 : 4655 - 4656
[22] Retreatment (ReTx) of patients (Pts) with refractory large B cell lymphoma (LBCL) sith Axicabtagene Ciloleucel (Axi-Cel) in ZUMA-1
Locke, F. L.
Bartlett, N. L.
Jacobson, C. A.
Oluwole, O. O.
Munoz, J.
Lekakis, L. J.
Topp, M. S.
Avivi, I
Kim, J. J.
Chu, R.
Zheng, L.
Rossi, J. M.
Bot, A.
Neelapu, S. S.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 57 - 57
[23] Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma
Topp, Max
Van Meerten, Tom
Houot, Roch
Minnema, Monique C.
Milpied, Noel
Lugtenburg, Pieternella J.
Thieblemont, Catherine
Wermke, Martin
Song, Kevin
Avivi, Irit
Kuruvilla, John
Duhrsen, Ulrich
Chu, Rachel
Zheng, Lianqing
Plaks, Vicki
Kerber, Anne
Kersten, Marie Jose'
BLOOD, 2019, 134
[24] Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (liso-cel) Vs Axicabtagene Ciloleucel (axi-cel) and Tisagenlecleucel in Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Maloney, David G.
Kuruvilla, John
Fox, Christopher P.
Cartron, Guillaume
Li, Daniel
Hasskarl, Jens
Bonner, Ashley
Zhang, Yixie
Liu, Fei Fei
BLOOD, 2020, 136
[25] Retreatment (reTx) of patients (pts) with refractory large B-cell lymphoma with axicabtagene ciloleucel (axi-cel) in ZUMA-1.
Locke, Frederick Lundry
Bartlett, Nancy L.
Jacobson, Caron A.
Oluwole, Olalekan O.
Munoz, Javier
Lekakis, Lazaros J.
Topp, Max S.
Avivi, Irit
Kim, Jenny J.
Chu, Rong
Zheng, Lianqing
Rossi, John M.
Bot, Adrian
Neelapu, Sattva Swarup
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[26] Primary Analysis of ZUMA-7: A Phase 3 Randomized Trial of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL)
Chaganti, Sridhar
Cwynarski, Kate
Cunningham, David
Locke, Frederick L.
Miklos, David B.
Jacobson, Caron A.
Perales, Miguel-Angel
Kersten, Marie Jose
Oluwole, Olalekan O.
Ghobadi, Armin
Rapoport, Aaron P.
McGuirk, Joseph P.
Pagel, John M.
Munoz, Javier
Farooq, Umar
van Meerten, Tom
Reagan, Patrick M.
Sureda, Anna
Flinn, Ian W.
Vandenberghe, Peter
Song, Kevin W.
Dickinson, Michael
Minnema, Monique C.
Riedell, Peter A.
Leslie, Lori A.
Yang, Yin
Filosto, Simone
Schupp, Marco
To, Christina
Cheng, Paul
Gordon, Leo I.
Radford, John
Westin, Jason R.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 20 - 22
[27] Product attributes of axicabtagene ciloleucel (axi-cel) that associate differentially with efficacy and toxicity in second-line large B-cell lymphoma
Filosto, Simone
Vardhanabhuti, Saran
Canales, Miguel
Poire, Xavier
Lekakis, Lazaros J.
de Vos, Sven
Portell, Craig A.
Wang, Zixing
To, Christina
Cheng, Paul
Chou, Justin
Bot, Adrian
Shen, Rhine
Westin, Jason R.
CANCER RESEARCH, 2022, 82 (12)
[28] Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6
Oluwole, Olalekan O.
Forcade, Edouard
Munoz, Javier
de Guibert, Sophie
Vose, Julie M.
Bartlett, Nancy L.
Lin, Yi
Deol, Abhinav
McSweeney, Peter A.
Goy, Andre H.
Kersten, Marie Jose
Jacobson, Caron A.
Farooq, Umar
Minnema, Monique C.
Thieblemont, Catherine
Timmerman, John
Stiff, Patrick
Avivi, Irit
Tzachanis, Dimitrios
Zheng, Yan
Vardhanabhuti, Saran
Nater, Jenny
Shen, Rhine R.
Miao, Harry
Kim, Jenny
van Meerten, Tom
BLOOD, 2022, 140 : 10399 - 10401
[29] Long-Term Efficacy and Immune Reconstitution with Bendamustine As a Lymphodepleting Agent for Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory or Relapsed Large B-Cell Lymphoma (LBCL)
Bharadwaj, Sushma
Lau, Eric
Goyal, Anmol
Hamilton, Mark P.
Srinagesh, Hrishikesh
Jensen, Alexandria
Syal, Shriya
Mallampet, Jayasindhu
Latchford, Theresa
Sahaf, Bita
Weng, Wen-Kai
Smith, Melody
Maecker, Holden T.
Frank, Matthew J.
Miklos, David B.
Dahiya, Saurabh
BLOOD, 2023, 142
[30] Association of Metabolic Tumor Volume (MTV) and Clinical Outcomes in Second-Line (2L) Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Following Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in ZUMA-7
Locke, Frederick L.
Oluwole, Olalekan O.
Kuruvilla, John
Thieblemont, Catherine
Morschhauser, Franck
Salles, Gilles
Rowe, Steven P.
Vardhanabhuti, Saran
Filosto, Simone
To, Christina
Cheng, Paul
Schupp, Marco
Korn, Ronald
Kersten, Marie Jose
BLOOD, 2022, 140

← 1 2 3 4 5 →